Giant cell arteritis

10 trials MedDRA PT
10 Registered trials
0 Recruiting
7 Unique sponsors
9 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
H Endocrinology (ATC H) 2
L Oncology (ATC L) 2
J Anti-infectives (ATC J) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Corticosteroid 2 substances
JAK inhibitor 1 substance
Monoclonal antibody (human) 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Receptor fusion protein 1 substance
Phase III: 6 Phase II: 2 Phase IV: 1 Phase I (Other): 1

Filter these 10 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 10 trials

Phase III

6 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    PREDNISOLONE; UPADACITINIB
    2023-505476-29-00 10 countries 2019 n=201
    Ended
  • Novartis Pharma AG Commercial
    IMP not specified
    2024-510744-31-00 17 countries 2021 n=243
    Ended
  • Novartis Pharma AG Commercial
    SECUKINUMAB
    2024-512856-40-00 1 country 2022 n=146
    Ended
  • Assistance Publique Hopitaux De Paris Academic
    IMP not specified
    2024-511906-21-00 1 country 2021 n=60
    Ended
  • Centre Hospitalier Universitaire De Dijon Academic
    PREDNISONE; TOCILIZUMAB
    2024-512269-14-00 1 country 2020 n=230
    Ended
  • Trustees Of The University Of Pennsylvania Academic
    ABATACEPT
    2024-515287-31-00 2 countries n=16
    Pending

Phase II

2 trials
  • Assistance Publique Hopitaux De Paris Academic
    IMP not specified
    2024-517030-17-00 1 country n=40
    Pending
  • Universitair Medisch Centrum Groningen Academic
    (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE
    2024-511977-31-01 1 country n=30
    Pending

Phase IV

1 trial
  • Region Skane Academic
    RESPIRATORY SYNCYTIAL VIRUS, GLYCOPROTEIN F, RECOMBINANT, STABILISED IN THE PRE-FUSION CONFORMATION, ADJUVANTED WITH AS01E; RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847A, RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP B, STABILIZED PREFUSION F PROTEIN 847B
    2024-518191-31-00 1 country n=180
    Pending

Phase I (Other)

1 trial
  • Novartis Pharma AG Commercial
    IMP not specified
    2023-507667-19-00 4 countries 2024 n=24
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma AG Commercial 3 Phase I (Other), Phase III 0
Assistance Publique Hopitaux De Paris Academic 2 Phase II, Phase III 0
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase III 0
Universitair Medisch Centrum Groningen Academic 1 Phase II 0
Centre Hospitalier Universitaire De Dijon Academic 1 Phase III 0
Trustees Of The University Of Pennsylvania Academic 1 Phase III 0
Region Skane Academic 1 Phase IV 0
New trials by year
2019
1
2020
1
2021
2
2022
1
2024
1
← All indication landscapes